Do atypical antipsychotics cause stroke?

CNS Drugs

Volumn 19, Issue 2, 2005, Pages 91-103

  Herrmann, Nathan ^a,b   Lanctôt, Krista L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; ZIPRASIDONE;

ATHEROSCLEROSIS; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DATA BASE; DEHYDRATION; DEMENTIA; DISEASE ASSOCIATION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HEMOCONCENTRATION; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; MENTAL DISEASE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SOMNOLENCE; STROKE; THROMBOEMBOLISM; VENOUS STASIS; VENOUS THROMBOEMBOLISM;

ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; BENZODIAZEPINES; CEREBROVASCULAR ACCIDENT; DEMENTIA; HUMANS; MEDLINE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; RISPERIDONE; TREATMENT OUTCOME;

EID: 14644396191     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519020-00001     Document Type: Review

References (55)

1. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci 2001; 28 Suppl. 1: S96-107
2. Semla TP, Palla K, Podding B, et al. Effect of the omnibus reconciliation act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42: 648-52
3. American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus statement on improving the quality of mental health care in US nursing homes: management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003; 51: 1287-98
4. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154-66
5. Committee on Safety of Medicines. Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia [online]. Available from URL: http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm [Accessed 2004 Jun 28]
6. Review Manager (Rev Man) [computer programme]. Version 4.2 for Windows. Oxford: The Cochrane Collaboration, 2002
7. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-70
8. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395
9. Greenspan A, Eerdekens M, Mahmoud R. Is there an increased risk of cerebrovascular adverse events among dementia patients treated with risperidone? Proceedings of the Annual Meeting of the International College of Geriatric Psychoneuropharmacology; 2003 Dec 12-14; San Juan
10. Greenspan A, Eerdekens M, Mahmoud R. Is there an increased rate of cerebrovascular adverse events with risperidone in patients with dementia? [abstract]. Int J Neuropsychopharmacol 2004; 7 Suppl. 1: S205
11. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43
12. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55
13. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107-15
14. Data on file, Janssen, 2004
15. Cavazzoni P, Young C, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. Proceedings of the 44th Annual New Clinical Drug Evaluation Unit; 2004 Jun 1-4; Phoenix
16. Data on file, Eli Lilly, 2004
17. Street JS, Clarke S, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. Arch Gen Psychiatry 2000; 57: 968-76
18. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-26
19. Feigin VL, Lawes CMM, Bennett DA, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53
20. Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 1996; 312: 608-11
21. Ostbye T, Hill G, Steenhuis R. Mortality in elderly Canadians with and without dementia: a 5-year follow-up. Neurology 1999; 53: 521-6
22. American Association of Geriatric Psychiatry. What to consider in evaluating evidence: the case of the risperidone warning: an AAGP teleconference [online]. Available from URL: http:// www.aagpgpa.org/members/risperidone.asp [Accessed 2004 May 31]
23. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses: sometimes informative, usually misleading. BMJ 1999; 318: 1548-51
24. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-41
25. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-23
26. Kortepeter C, Chen M, Knudsen JF. Clozapine and venous thromboembolism. Am J Psychiatry 2002; 159: 876-7
27. DeClerck F, Somers Y, Mannaert E, et al. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther 2004; 26: 1261-73
28. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypothesis for underlying mechanism. J Am Med Dir Assoc 2004; 5: 129-32
29. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101
30. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 2003; 25: 605-10
31. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke 2000; 31: 2307-13
32. Hossain M, Ooi WL, Lipsitz LA. Intra-individual postural blood pressure variability and stroke in elderly nursing home residents. J Clin Epidemiol 2001; 54: 488-94
33. Yavuz D, Deyneli D, Akpinar I, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol 2003; 149: 187-93
34. Wallaschofski H, Donné M, Eigenthaler M, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001; 86: 5912-9
35. Kinon BJ, Stauffer VL, McGuire HC, et al. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients. J Am Med Dir Assoc 2003; 4: 189-94
36. Ray JG. Evidence in upheaval: incorporating observational data into clinical practice. Arch Intern Med 2002; 162: 249-54
37. Liperoti R, Gambassi G, Lapane K, et al. Cerebrovascular events among elderly patients treated with conventional or atypical antipsychotics. Proceedings of the Annual Meeting of the American Geriatrics Society; 2004 May 17-21; Las Vegas
38. Kozma C, Engelhart L, Long S, et al. No evidence for relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. Proceedings of the Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York
39. Herrmann N, Mamdani M, Lanctôt KL. Atypical antipsychotics and risk of Cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
40. Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002; 59: 1721-9
41. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002; 287: 2090-7
42. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA 1982; 248: 333-5
43. Evans LK, Strumpf NE. Tying down the elderly: a review of the literature on physical restraint. J Am Geriatr Soc 1989; 37: 65-74
44. Merrian AE, Aronson MK, Gaston P, et al. The psychiatric symptoms of Alzheimer's disease. J Am Geriatr Soc 1988; 36: 7-12
45. Lopez OL, Wisniewski SR, Becker JT, et al. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56: 1266-72
46. Lanctôt KL, Best TS, Mittmann N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59: 550-61
47. Schneider L, Dagerman K. Meta-analysis of atypical antipsychotics for dementia patients balancing efficacy and adverse events. Int Psychogeriatr 2003; 15 (2 Suppl.): 164-5
48. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716-9
49. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004 Jul 10; 329 (7457): 75
50. Opie J, Rosewarne R, O'Connor DW. The efficacy of psychosocial approaches to behavior disorders in dementia: a systematic literature review. Aust N Z J Psychiatry 1999; 33: 789-99
51. Gromley N, Lyons D, Howard R. Behavioral management of aggression in dementia: a randomized controlled trial. Age Ageing 2001; 30: 141-5
52. Opie J, Doyle C, O'Connor DW. Challenging behaviors in nursing home residents with dementia: a randomized controlled trial of multidisciplinary interventions. Int J Geriatr Psychiatry 2002; 17: 6-13
53. Brodaty H, Draper BM, Millar J, et al. Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. J Clin Psychiatry 2003; 64: 63-72
54. Ballard CG, O'Brien JT, Reichelt K, et al. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind placebo-controlled trial with Melissa. J Clin Psychiatry 2002; 63: 553-8
55. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271-8